Survodutide Clears CV Safety Bar but Weight and Tolerability Cap Obesity Ambition

Survodutide Demonstrates Cardiovascular Safety in Phase 3 Trial

Zealand and Boehringer Ingelheim's weight loss drug, survodutide, demonstrated non-inferiority to placebo regarding cardiovascular safety in the Phase 3 SYNCHRONIZE-CVOT study. The trial, involving 5,530 adults with overweight or obesity and cardiovascular risk factors, showed survodutide did not increase the risk of major cardiovascular events like heart attack, stroke, or cardiovascular death. While the results support global regulatory submissions, analysts expressed skepticism about the drug's broader utility beyond patients with liver-related risk factors, citing tolerability concerns and lower weight loss efficacy compared to competitors. The study also reported reductions in systolic blood pressure and waist circumference.

• The SYNCHRONIZE-CVOT study successfully established survodutide's non-inferiority to placebo in preventing major cardiovascular events, addressing prior concerns about potential heart-related side effects. Despite this positive safety outcome, analysts from William Blair believe the drug's clinical use will likely be confined to patients with elevated liver-related risk factors, suggesting limited utility beyond this specific population due to tolerability issues and competitive efficacy.
• Beyond its primary cardiovascular safety objective, survodutide demonstrated positive outcomes on key secondary endpoints. The trial showed a significant reduction in systolic blood pressure and waist circumference at 72 weeks compared to placebo. These detailed results were presented at the American Heart Association Scientific Sessions and concurrently published in The Lancet, lending scientific credibility to the findings.
• The study reported a high rate of discontinuations in the treatment groups (19.3% and 20.8% for low and high doses, respectively) compared to placebo (1.9%), primarily due to gastrointestinal side effects such as nausea, vomiting, diarrhea, and constipation. Zealand attributed these discontinuations to limited flexibility in the initial study protocol's dose escalation phase, stating that ongoing studies incorporate more flexible titration strategies to improve tolerability and better reflect real-world usage.
• Survodutide achieved approximately 13% body weight reduction, which is notably lower than competitors like Eli Lilly's retatrutide (28.3%) and other incretins (around 20%). This efficacy gap has led the partners to emphasize other benefits, such as the cardiovascular safety profile. The SYNCHRONIZE-CVOT study is part of a larger clinical program for survodutide, which also includes ongoing investigations for MASH (metabolic dysfunction-associated steatohepatitis) and fibrosis, indicating a strategy to target specific patient populations where its profile might be more advantageous.

Survodutide's Safety Profile: Addressing CV Risk and Tolerability

Across obesity trials, survodutide showed a high incidence of adverse events driven by gastrointestinal symptoms. In the 46-week phase 2 dose-finding trial in participants with BMI ≥27 kg/m without diabetes, adverse events occurred in 281 (91%) of 309 survodutide recipients and 58 (75%) of 77 placebo recipients, primarily gastrointestinal in 232 (75%) of 309 survodutide recipients and 32 (42%) of 77 placebo recipients, with all tested doses of 0.6, 2.4, 3.6, or 4.8 mg described as tolerated. In the phase 3 SYNCHRONIZE-1 trial in adults with obesity without diabetes, gastrointestinal symptoms (typically mild to moderate) occurred in 80.9% of participants in the 3.6-mg group, in 89.7% of those in the 6.0-mg group, and in 47.9% of those in the placebo group, with no deaths reported. A subgroup analysis of the phase 2 obesity trial found rates of adverse events were comparable between subgroups for sex and baseline BMI, with nausea the most frequently reported gastrointestinal adverse event in all subgroups.

In metabolic dysfunction-associated steatohepatitis (MASH) and cirrhosis populations, a similar gastrointestinal-predominant profile was observed without an increase in serious events. In the 48-week phase 2 trial in biopsy-confirmed MASH with fibrosis stage F1 through F3, adverse events more frequent with survodutide than placebo included nausea (66% vs. 23%), diarrhea (49% vs. 23%), and vomiting (41% vs. 4%), while serious adverse events occurred in 8% with survodutide and 7% with placebo. In the phase 1 trial in cirrhosis, drug-related adverse events occurred in 25.0% of healthy individuals and ≤25.0% of those with cirrhosis after single 0.3 mg doses, and 82.4% and 87.5%, respectively, of the multiple-dose cohorts over 28 weeks with escalation from 0.3 mg to 6.0 mg, with survodutide described as generally tolerable in people with compensated or decompensated cirrhosis and not requiring pharmacokinetic-related dose adjustment.

Dose dependency of tolerability events and discontinuations is consistent across pooled and early-phase data. A systematic review and meta-analysis of 3 RCTs (1088 patients) found survodutide 2.4 mg [odds ratio (OR): 2.93 (95% CI: 1.66, 5.18)] and 3.6 mg [OR: 4.61 (95% CI: 2.33, 9.12)] was associated with significantly higher treatment-emergent adverse events compared to placebo, although severe adverse events were not increased, with gastrointestinal adverse events predominant and dose dependent and treatment discontinuation due to adverse events significantly higher and dose dependent. In healthy Japanese men with overweight/obesity receiving BI 456906, 10 participants (37.0%) withdrew from dose escalation due to adverse events (amylase increase, n=1; decreased appetite, n=9), higher in the 4.8 mg once-weekly group (n=6, 66.7%) versus the 1.8 mg once-weekly and 2.4 mg twice-weekly groups (both n=2, 22.2%), with drug-related adverse events reported for all participants receiving BI 456906 and four receiving placebo, most frequently decreased appetite (n=24, 66.7%), and no unexpected tolerability concerns. Adverse events, primarily gastrointestinal intolerance and modest heart rate increases, remain important limitations, contributing to discontinuation rates higher than comparator agents.

Survodutide's Efficacy in a Crowded Obesity Landscape

Published studies in overweight and obesity compare dual-pathway incretin therapies, combination regimens, and surgery against single-agent GLP-1 receptor agonists, metformin alone, and diet and exercise. Tirzepatide 15 mg and CagriSema achieved the greatest weight reduction among pharmacotherapies, while sleeve gastrectomy achieved greater weight loss than semaglutide at 12 months.

Beyond Obesity: Survodutide's Broader Therapeutic Potential

Survodutide, a glucagon receptor/glucagon-like peptide-1 receptor dual agonist, is being investigated beyond overweight and obesity across metabolic liver disease, type 2 diabetes, cirrhosis, and cardiovascular risk populations. These trials span phase 1 to phase 3 and predominantly use randomized, double-blind, placebo-controlled designs with once-weekly subcutaneous administration and dose-escalation to maintenance phases.

• At-risk metabolic dysfunction-associated steatotic liver disease (MASLD): SYNCHRONIZE-MASLD phase 3, randomized, double-blind, placebo-controlled trial in 216 adults with obesity and at-risk MASLD defined by MASLD with evidence of liver inflammation and/or fibrosis by noninvasive tests or biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH), randomized (2:1) to once-weekly subcutaneous survodutide 6.0 mg (n = 146) or placebo (n = 70) to week 48.

• Biopsy-confirmed MASH with fibrosis stage F1 through F3: 48-week phase 2 trial in 293 participants randomized in a 1:1:1:1 ratio to once-weekly subcutaneous survodutide 2.4, 4.8, or 6.0 mg or placebo, with a 24-week rapid-dose-escalation phase followed by a 24-week maintenance phase.

• Type 2 diabetes on metformin background: Phase II, multicentre, randomised, double-blind, parallel-group, placebo-controlled trial in participants aged 18-75 years with type 2 diabetes, HbA1c 53-86 mmol/mol (7.0-10.0%) and BMI 25-50 kg/m², randomized to survodutide (up to 0.3, 0.9, 1.8 or 2.7 mg once weekly or 1.2 or 1.8 mg twice weekly), placebo, or open-label semaglutide (up to 1.0 mg once weekly) for 16 weeks' treatment.

• Cirrhosis including MASH-related cirrhosis: Multinational, non-randomized, open-label, phase I trial with initial single subcutaneous survodutide 0.3 mg dose in people with Child-Pugh class A, B or C cirrhosis and healthy individuals matched for age, sex, and weight, followed by once-weekly subcutaneous doses escalated from 0.3 mg to 6.0 mg over 24 weeks then maintained for 4 weeks in people with overweight/obesity with or without cirrhosis (Child-Pugh class A or B).

• Cardiovascular safety in increased cardiovascular risk: SYNCHRONIZE-CVOT phase 3, randomized, double-blind, parallel-group, event-driven study of once-weekly subcutaneous survodutide versus placebo in adults with BMI ≥27 kg/m² and established cardiovascular disease or chronic kidney disease, and/or at least 2 weight-related complications or risk factors for cardiovascular disease, with primary endpoint of time to first occurrence of composite adjudicated 5-point major adverse cardiovascular events and target recruitment of 4,935 participants.